These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4826562)

  • 1. Evaluation of monodansylcadaverine for effects on tumor growth.
    Yancey ST; Laki K
    J Natl Cancer Inst; 1974 Mar; 52(3):733-5. PubMed ID: 4826562
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppression of in vivo growth of mouse myelomas by purified rabbit antibodies against mouse myeloma cells.
    Yutoku M; Grossberg AL; Pressman D
    J Natl Cancer Inst; 1974 Jul; 53(1):201-7. PubMed ID: 4835105
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of intraperitoneal pristane on established immunity to the adj-PC-5 plasmacytoma.
    Potter M; Walters JL
    J Natl Cancer Inst; 1973 Sep; 51(3):875-81. PubMed ID: 4743559
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of HIPA plasmacytoma cell-free transmission by normal spleen of BALB-c, DBA-2 and C3H mice.
    Pedio G; Rüttner JR
    Int J Cancer; 1971 Nov; 8(3):497-502. PubMed ID: 5137311
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacology of 3,5-diamino-1,24-triazole (guanazole). 1. Antitumor activity of guanazole.
    Hahn MA; Adamson RH
    J Natl Cancer Inst; 1972 Mar; 48(3):783-90. PubMed ID: 4621741
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibitory effect of endotoxin on the growth of plasma cell tumor.
    Bober LA; Kranepool MJ; Hollander VP
    Cancer Res; 1976 Mar; 36(3):927-9. PubMed ID: 766964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of protective activity of BALB-c spleen homogenate against cell-free transmission of HIPA-plasmacytoma by pretreatment with mineral oil of spleen-donor mice.
    Pedio G; Rüttner JR; Odermatt BF
    Pathol Microbiol (Basel); 1972; 38(5):375-8. PubMed ID: 4648589
    [No Abstract]   [Full Text] [Related]  

  • 8. Dansyl cadaverine: a fluorescent probe and marker in cell membrane studies.
    Pincus JH; Chung SI; Chace NM; Gross M
    Arch Biochem Biophys; 1975 Aug; 169(2):724-30. PubMed ID: 1237273
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on a cell line derived from the L1210 murine leukemia with altered surface properties and decreased capacity for tumor production.
    Kessel D; Bosmann HB
    Cancer Res; 1974 Mar; 34(3):603-8. PubMed ID: 4855835
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
    Hiramoto RN; Ghanta VK
    Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of transplantation resistance to murine L1210 leukemia cells in BCG-primed mice by immunization with tuberculin protein-coupled L1210 cells.
    Ohno R; Kodera Y; Ogura M; Yamada H
    Gan; 1984 Feb; 75(2):187-92. PubMed ID: 6428959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
    Dombernowsky P; Nissen NI
    Acta Pathol Microbiol Scand A; 1973 Sep; 81(5):715-24. PubMed ID: 4771975
    [No Abstract]   [Full Text] [Related]  

  • 14. An experimental model for evaluation of factors in tumor escape from immunological attack.
    Yutoku M; Fuji H; Grossberg AL; Pressman D
    Cancer Res; 1975 Mar; 35(3):734-9. PubMed ID: 1116132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
    Somerville L; Cory AH; Cory JG
    In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant induced resistance to tumor development in mice.
    Hibbs JB; Lambert LH; Remington JS
    Proc Soc Exp Biol Med; 1972 Mar; 139(3):1053-6. PubMed ID: 5023755
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonmalignancy of hybrids derived from two mouse malignant cells. I. Hybrids between L1210 leukemia cells and malignant L cells.
    Jami J; Ritz E
    J Natl Cancer Inst; 1973 Nov; 51(5):1647-53. PubMed ID: 4762938
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
    [No Abstract]   [Full Text] [Related]  

  • 20. [Stress-induced decrease in body resistance to tumor growth and the prevention of this phenomenon by central inhibitory metabolites].
    Sukhikh GT; Meerson FZ; Mikhaleva II
    Dokl Akad Nauk SSSR; 1984; 278(1):253-6. PubMed ID: 6548436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.